Form 4: Inovio Pharmaceuticals Director Lota S. Zoth Reports Stock Option and Restricted Stock Unit Grants

Director Lota S. Zoth reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Summary

• On May 21, 2024, Lota S. Zoth, a director of Inovio Pharmaceuticals, received stock options for 2,917 shares and 2,167 restricted stock units (RSUs).
• The options have an exercise price of $10.99 and will vest 100% on May 21, 2025, expiring on May 21, 2034.
• The RSUs represent a contingent right to receive one share of common stock each and will vest 100% on May 21, 2025.
• Following these transactions, Zoth directly owns 2,917 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options and RSUs to a director, which is generally viewed as a positive sign of aligning interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for compensating directors of publicly traded companies, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Equity grants to non-employee directors are a common practice in the pharmaceutical industry.
• Companies like Moderna and BioNTech also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry norms for companies of similar size and stage of development.

Stakeholder Impact

• The grant of equity may have a slightly dilutive effect on existing shareholders.
• The equity grants incentivize the director to act in the best interests of the shareholders.

Key Dates